### 8. Immunomodulators and antineoplastics

#### 8.1. Immunomodulators for non-malignant disease

**Azathioprine**

**Indication**

Failure or rejection of transplanted organs or tissues

**ATC codes:** L04AX01 EMLc

**Indication**

ICD11 code: NE84

**INN**

Azathioprine

**Medicine type**

Chemical agent

**List type**

Complementary

**Formulations**

- Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
- Oral > Solid: 50 mg

**EML status history**

- First added in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Changed in 2002 (TRS 914)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)

**Sex**

All

**Age**

Also recommended for children

**Therapeutic alternatives**

The recommendation is for this specific medicine

**Patent information**

- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**

Azathioprine

**DrugBank**

Azathioprine

### Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee endorsed the inclusion of azathioprine on the complementary list of the EMLc for use as an immunosuppressive medicine. Given the limited information available on the use of azathioprine and ciclosporin in children, the Subcommittee recommended that reviews be commissioned for both drugs for consideration at the next meeting for the EMLc. The Subcommittee also requested information on the availability of paediatric-appropriate forms. In reviewing the section of the list for antineoplastic and immunosuppressive medicines, the Subcommittee recognized the importance of access to these medicines. Furthermore, the need for access to specialist centres was emphasized. The list of immunosuppressants and cytotoxics was thought to be comprehensive. The EMLc Subcommittee agreed that the currently listed medicines should be retained, even though the evidence for efficacy and safety in children was not reviewed. The medicines should be linked to treatment protocols.